Yale Cancer Center

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Yale Cancer Center

https://www.yalecancercenter.org/

ASCO® 2024
Yale Cancer Answers
ASH CME Series
Smilow Shares with Primary Care
Grand Rounds
Head and Neck Leukemia Myeloma Benign Hematology MDS and MPN Skin GYN Supportive & Palliative Care GU Breast CNS GI General Oncology Lymphoma Brain Lung Business
Head and Neck
Gynecologic
Benign Hematology
Breast
GI
Lung
GU
Hematologic Oncology
Brain
Cancer Screening
DEI (Diversity, Equity and Inclusion)
2021 ASH Highlights
General Events
Yale Liver Cancer Symposium 2019 Yale Cancer Center Immuno-Oncology Symposium 2019 2018 Yale Pancreas Symposium
Events

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

10 seconds

Playback speed

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

Navigating the Terrain: Recent Treatment Strategies for EGFRm Advanced NSCLC

By Yale Cancer Center FEATURING Amin Nassar

490 views

February 7, 2024

Disclaimer: On February 16, 2024, the FDA approved osimertinib (TAGRISSO®) with platinum-based chemotherapy for patients with la/mNSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

Comments 0